Key facts
- It has raised $89.7M; the latest was Later Stage VC ($3.1M) in Aug 2024.
- Notable investors include Eli Lilly and Company Foundation, Devon Park Bioventures, Endo Investors, McDonald Partners, Medicxi — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Diasome
- ·The full record, as it builds
Funding rounds
No funding rounds for Diasome are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Diasome
Developer of novel and cell-targeted therapies designed to treat diabetes, obesity, and other metabolic conditions. The company's therapies leverage technology, an insulin additive, to lessen the instances of high and low blood sugar levels in people with diabetes, enabling patients to get novel proprietary liver-targeted insulins for both Type one and Type two diabetes easily.
- Sector
- Healthcare
- HQ
- Cleveland, OH, United States
- Founded
- 2004
- Employees
- 10
- Website
- diasome.com/
- Ownership
- Privately Held (backing)
Diasome doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Diasome shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Diasome in its N-PORT filings yet. We sweep new filings monthly.